Coign Capital Advisors LLC Invests $744,000 in AbbVie Inc. $ABBV

Coign Capital Advisors LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,213 shares of the company’s stock, valued at approximately $744,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Evolution Wealth Management Inc. bought a new position in shares of AbbVie during the second quarter worth $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie during the 2nd quarter worth $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the 2nd quarter worth $36,000. Delos Wealth Advisors LLC bought a new position in AbbVie during the second quarter worth about $39,000. Finally, Bear Mountain Capital Inc. grew its stake in AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.9%

NYSE ABBV opened at $218.05 on Friday. The firm’s 50 day moving average is $225.87 and its 200-day moving average is $216.99. The company has a market capitalization of $385.38 billion, a PE ratio of 165.19, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Analyst Ratings Changes

A number of research firms have recently commented on ABBV. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Citigroup lowered their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Bank of America lifted their price target on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Morgan Stanley upped their price target on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Finally, Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $248.11.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.